Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide and Hypofractionated Radiotherapy for Intermediate Risk Prostate Cancer
NCT03196388Phase 2Unknown
- Sponsor
- Fundación Canaria de Investigación Sanitaria
- Start
- Dec 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in prostate carcinoma, sponsored by Fundación Canaria de Investigación Sanitaria. Primary endpoint: Number of patients with >= 80% reduction of baseline PSA at 25 weeks. Status: unknown.
02
Drugs
enzalutamide
03
Conditions
prostate carcinoma
Beyond the preview
Go deeper on NCT03196388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03196388.